MCE Webinar: Probing for Antimalarial Drug Targets – The Old and The New
About this webinar
Malaria, caused by the Plasmodium parasite, remains one of the world’s most pressing health threats. With drug resistance reducing the effectiveness of current treatments, new therapeutic strategies are urgently needed.
In this MedChemExpress hosted webinar, Dr Brad Sleebs will share insights from his research on novel antimalarial compounds, including how drug-like small molecules were screened, optimised, and validated across different life cycle stages of P. falciparum. He will highlight the mechanisms of action of two promising hit classes and demonstrate their efficacy across mosquito transmission and mouse models.
What you will learn
• Cutting-edge models for characterising antimalarials at an early stage of development
• Approaches for identifying the mechanism of action of antimalarials
• Antimalarial drug targets essential for regulating Na+ homeostasis
About the Speaker
Dr Sleebs is a Laboratory Head in the New Medicines and Diagnostics Division at the Walter and Eliza Hall Institute. His work spans the development of small-molecule probes and drug discovery programs in collaboration with leading partners, including Janssen Pharmaceuticals, Medicines for Malaria Venture, and MSD.
